AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$VCEL

Vericel Corp (VCEL) (Q3 2026) Earnings Call Highlights: Record Revenue and Tripled Net

Vericel Corp (VCEL) reported record Q3 2026 revenue and tripled net income. CEO Nick Colangelo highlighted balanced growth in MACI, driven by new surgeons and deeper penetration. CFO Joe Mara noted strong biopsy growth translating into procedures. The company expects high-30% EBITDA margins in the next few years. MACI Arthro is penetrating smaller defects, and NexoBrid saw $3M Q3 revenue with more expected.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 11:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vericel Corp (VCEL) (Q3 2026) Earnings Call Highlights: Record Revenue and Tripled Net — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$VCELBullishMed
01

Why it matters

The earnings beat and cash‑rich position suggest upside potential, but future guidance remains cautious.

02

Market read

Earnings beat and cash generation could drive short‑term upside for VCEL and related biotech stocks.

03

What to watch

Potential reliance on BARDA contracts and MACI market share concentration.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

Vericel Corp reported its Q3 2026 earnings, noting record revenue, margin expansion, and cash generation.

Company-level read

Ticker impact

$VCELBullishHigh confidence
Context

Q3 2026 earnings call disclosed record revenue, strong MACI growth, BARDA agreement revenue, and cash flow enabling buybacks.

Expected impact

likely upward pressure as market prices in better-than-expected results and cash‑rich balance sheet.

Evidence & confidence

Management highlighted record revenue and margin expansion, plus cash enabling share repurchases, which are bullish signals.

Market effects

Sector

Strong performance may lift other regenerative medicine and biotech peers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

If guidance for 2027 is modest, the rally could be short‑lived.

Key entities

  • Company
    Vericel Corp

    US‑listed regenerative medicine company.

  • Executive
    Nick Colangelo

    CEO of Vericel, provided commentary on growth and BARDA agreement.

  • Executive
    Joe Mara

    CFO of Vericel, discussed margins and cash flow.

Read at source← All news

StoryVericel posts record Q3 profit, lifts 2026 revenue and EBITDA margin guidance

Also covered by

6 outlets

Related articles

$VCELHighAI 8/10

Truist raises Vericel stock price target on MACI growth momentum

Truist Securities raised its price target for Vericel (VCEL) to $65 from $52, citing strong Q3 results and growth momentum in its MACI product line. The company reported record surgeon additions, biopsies, and implants, along with upside in its Burn Care segment. VCEL's stock surged 28.6% in the past week, trading near its 52-week high. The company posted 25.3% revenue growth over the last twelve months with a 74.5% gross profit margin.

investing.com
$VCELMed

Vericel Corp (VCEL) Q3 2026 Earnings Call Transcript

Vericel Corp (VCEL) reported Q3 2026 record revenue of $67M, up 21% YoY, driven by MACI's strong performance. MACI biopsies, implants, and surgeon adoption increased, with MACI Arthro gaining momentum. Burn care business also saw record revenue of $18M, up 50% YoY. The company raised its Q4 revenue guidance.

finance.yahoo.com